Myriad’s myPlan® Lung Cancer
Myriad’s myPlan® Lung Cancer
Myriad’s myPlan® Lung Cancer is a new RNA 46-gene expression signature based on cell cycle progression (CCP) genes —the genes that regulate cell division. myPlan Lung Cancer measures the expression levels of specific genes in combination with pathological stage to predict the 5-year risk of lung cancer death in patients with surgically resected early-stage NSCLC. The myPlan Lung Cancer Prognostic Score provides physicians with patient specific risk estimates to better predict the five-year risk of lung cancer-specific death (Bueno et al 2015). As an objective measure of tumor aggressiveness, the myPlan Lung Cancer prognostic score adds an important data point to help determine treatment options for patients with early stages of lung cancer. Current medical society guidelines for early stage NSCLC adenocarcinoma rely predominately on TNM staging to guide medical management. TNM is based primarily on the size and location of the tumor in early stage disease and serves as an indicator of disease progression. Particularly for patients with stage 1B lung adenocarcinoma, the benefit of adjuvant chemotherapy remains unclear. For these patients, myPlan can be used as a quantitative tool to more accurately identify patients at high risk, who may be over or under treated at present. myPlan has been validated in 4 multinational retrospective studies containing over 2200 patients with stage I-II lung adenocarcinoma. For more information on myPlan Lung Cancer and to begin testing, please contact Yanet Aleaga at 305.992.7563 or email yaleaga@myriad.com.
